Clinical trials

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tag
Showing 0 of 100
Atacicept
Antagonist of BAFF/APRIL
Subcutaneous
II/III
Atrasentan
Antagonist of endothelin A receptor
Oral
III
Bilisibimod (AMG623)
Selective inhibitor of BAFF
Subcutaneous
II/III
CCX168
Anti-C5a receptor antagonist
Oral
II
CM338
MASP2 inhibitors
Subcutaneous
II
Cemdisiran (ALN-CC5)
RNAi targeting complement C5
Subcutaneous
II
Fecal microbiota transplantation (FMT)
Transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient
Oral
NA
Felzartamab (MOR202)
Humanized IgG1 monoclonal antibody against CD38
Intravenous infusion
IIa
Fosfamatinib
Spleen tyrosine kinase (SYK) inhibitor
Oral
II
HR19042
The exact mechanism of action remains unknown, it falls under the category of small molecules
Oral
II
HRS-5965
Complement factor B modulators
Oral
II
Hydroxychloroquine
TLR signaling inhibitor
Oral
II
IONIS-FB-LRx
Antisense inhibitor of Complement Factor B
Subcutaneous
II
Iptacopan (LNP023)
Complement Factor B inhibitor
Oral
III
Mezagitamab (TAK-079)
Anti-CD38 human IgG1 monoclonal antibody
Subcutaneous
I
Pegcetacoplan (APL-2)
Complement C3 inhibitor
Subcutaneous
II
RO7434656
Antisense Inhibitor of Complement Factor B
Subcutaneous
III
Ravulizumab (ALXN1210)
Humanized anti-C5 monoclonal antibody
Intravenous infusion
II
SHR-2010
MASP2 inhibitors
Intravenous infusion/Subcutaneous
II
Sibeprenlimab (VIS649)
Humanized IgG2 against APRIL
Subcutaneous
III
Sparsentan
Selective antagonist of angiotensin II receptor and endothelin A receptor
Oral
III
Telitacicept
Dual inhibitor of BAFF/APRIL
Subcutaneous
III
Vemircopan (ALXN2050)
Factor D inhibitor
Oral
II
Zigakibart (BION-1301)
Humanized IgG4 against APRIL
Intravenous infusion/Subcutaneous
I/II
No results found.
There are no results with this criteria. Try changing your search.